Redhill Biopharma falls on plan to stop promotion of 2 gastrointestinal treatments
21/01/2020 15:09
** U.S.-listed shares of Israel-based drug developer
RDHL.O down 1.9% at $6.01
** Redhill Biopharma says it would discontinue its
co-promotion and commercialization agreements for
gastrointestinal treatments Donnatal and EnteraGam urn:newsml:reuters.com:*:nGNX28ZWnj
** Adds co will focus on products such as Talicia, an oral
combination drug targeting a type of bacterial infection, and
Aemcolo, a treatment of travelers’ diarrhea caused by
noninvasive strains of E. coli
** Talicia is planned to be launched in Q1 2020
** In 2019, U.S.-listed RDHL stock rose ~9.4%
(Reporting by Shivani Singh)
((ShivaniSingh1@thomsonreuters.com;))